|
17 Nov 2020 |
Jounce Therapeutics Receives Study May Proceed Letter from US FDA to Initiate Phase 1 Clinical Trial of JTX-8064 Targeting the LILRB2/ILT4 Mechanism
|
|
17 Nov 2020 |
Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148 in Patients with Advanced HER2‑Expressing Breast Cancer
|
|
17 Nov 2020 |
Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development
|
|
16 Nov 2020 |
Samsung Bioepis announces one-year results from Phase 3 study of SB11, a proposed biosimilar to Lucentis® (ranibizumab), at the American Academy of Ophthalmology (AAO) 2020 Virtual
|
|
16 Nov 2020 |
Calypso Biotech Announces Successful Dosing of First Phase 1 Cohort with Anti-Interleukin-15 (IL-15) Monoclonal Antibody CALY-002 for the Treatment of Autoimmune Diseases
|
|
16 Nov 2020 |
Innovent Announces the Results of the Phase I Clinical Trial of IBI302, a First-in-class Ophthalmic Recombinant Human Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2020 American Academy of Oph
|
|
15 Nov 2020 |
FDA issues Complete Response Letter for sutimlimab, an investigational treatment for hemolysis in adults with cold agglutinin disease
|
|
15 Nov 2020 |
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple‑Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)
|
|
13 Nov 2020 |
NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy at the American Academy of Ophthalmology 2020 Virtual
|
|
13 Nov 2020 |
CHMP recommends EU approval of Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer
|
|
13 Nov 2020 |
Akero Presents Additional Positive Data from Phase 2a BALANCED Study Demonstrating Potential of Efruxifermin as a Foundational NASH Monotherapy
|
|
13 Nov 2020 |
Silverback Therapeutics Presents Preclinical Data for SBT8230 at AASLD The Liver Meeting Digital Experience
|
|
13 Nov 2020 |
Acceleron Presents Preliminary Interim Data from the SPECTRA Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension (PAH) at the 2020 American Heart Association Scientific Sessions
|
|
13 Nov 2020 |
CHMP Adopted Positive Opinion for ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
|
|
13 Nov 2020 |
Harpoon Therapeutics Presents Encouraging Preclinical Data for HPN601 EpCAM ProTriTAC™ Program at 35th SITC Annual Meeting
|
|
13 Nov 2020 |
The CHMP has adopted a negative opinion for emapalumab in Europe for the treatment of primary HLH
|
|
13 Nov 2020 |
KAHR Announces First Patient Dosed in Phase 1/2 Clinical Trial of DSP107, Bi-Functional CD47x41BB Candidate for the Treatment of Solid Tumors
|
|
13 Nov 2020 |
Janssen Submits Applications in U.S. and EU Seeking Approval of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj)/DARZALEX® (daratumumab) Subcutaneous (SC) Formulation in Combination With Pomalidomide and Dexamethasone for Patients With Relapsed or Re
|
|
12 Nov 2020 |
Five Prime Presents First Preclinical Data on Anti-CCR8 Antibody FPA157
|
|
12 Nov 2020 |
Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients
|
|
12 Nov 2020 |
Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab
|
|
11 Nov 2020 |
Samsung Bioepis Initiates Phase 1 Clinical Trial for SB16, Proposed Biosimilar to Prolia (Denosumab)
|
|
11 Nov 2020 |
First Patient Dosed in Phase 1 Clinical Trial of Henlius Denosumab Biosimilar HLX14
|
|
11 Nov 2020 |
ImCheck Presents at SITC First Clinical Demonstration of Gamma Delta T Cell Activation and Tumor Infiltration with Positive Safety for ICT01
|
|
11 Nov 2020 |
Innovent Releases Phase 1a Results of CD47 Monoclonal Antibody (Letaplimab) in Monotherapy for Advanced Malignancies at SITC 2020
|
